S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Version 4.0 Dezember 2017 AWMF-Registernummer: OL
|
|
|
- Alvin Phelps
- 6 years ago
- Views:
Transcription
1 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms Version 4.0 Dezember 2017 AWMF-Registernummer: OL
2 Systemische Therapie des metastasierten Mammakarzinoms S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
3 Quellen: Stockler, M., N. Wilcken, D. Ghersi and R. Simes (1997). "The management of advanced breast cancer: systemic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy." Woolloomooloo, NHMRC National Breast Cancer Centre. Fossati, R., C. Confalonieri, V. Torri, E. Ghislandi, A. Penna, V. Pistotti, A. Tinazzi and A. Liberati (1998). "Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women." J Clin Oncol 16(10): Stockler, M., N. R. Wilcken, D. Ghersi and R. J. Simes (2000). "Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer." Cancer Treat Rev 26(3): NICE. (2009 [addendum 2014]). "The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment." from Partridge, A. H., R. B. Rumble, L. A. Carey, S. E. Come, N. E. Davidson, A. Di Leo, J. Gralow, G. N. Hortobagyi, B. Moy, D. Yee, S. B. Brundage, M. A. Danso, M. Wilcox and I. E. Smith (2014). "Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2- negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline." J Clin Oncol 32(29): Rugo, H. S., R. B. Rumble, E. Macrae, D. L. Barton, H. K. Connolly, M. N. Dickler, L. Fallowfield, B. Fowble, J. N. Ingle, M. Jahanzeb, S. R. Johnston, L. A. Korde, J. L. Khatcheressian, R. S. Mehta, H. B. Muss and H. J. Burstein (2016). "Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline." J Clin Oncol 34(25): S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
4 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
5 Quellen: Carrick, S., S. Parker, N. Wilcken, D. Ghersi, M. Marzo and J. Simes (2005). "Single agent versus combination chemotherapy for metastatic breast cancer." Cochrane Database Syst Rev(2): Cd Sledge, G. W., Jr., P. Hu, G. Falkson, D. Tormey and M. Abeloff (2000). "Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study." J Clin Oncol 18(2): S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
6 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
7 Quellen: Klijn, J. G., R. W. Blamey, F. Boccardo, T. Tominaga, L. Duchateau and R. Sylvester (2001). "Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials." J Clin Oncol 19(2): NICE. (2009 [addendum 2014]). "The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment." from NBOCC, N. B. a. O. C. C. (2010). Recommendations for use of Chemotherapy for the treatment of advanced breast cancer. Surry Hills. Rugo, H. S., R. B. Rumble, E. Macrae, D. L. Barton, H. K. Connolly, M. N. Dickler, L. Fallowfield, B. Fowble, J. N. Ingle, M. Jahanzeb, S. R. Johnston, L. A. Korde, J. L. Khatcheressian, R. S. Mehta, H. B. Muss and H. J. Burstein (2016). "Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline." J Clin Oncol 34(25): S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
8 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
9 Quellen: Taylor, C. W., S. Green, W. S. Dalton, S. Martino, D. Rector, J. N. Ingle, N. J. Robert, G. T. Budd, J. C. Paradelo, R. B. Natale, J. D. Bearden, J. A. Mailliard and C. K. Osborne (1998). "Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study." J Clin Oncol 16(3): NICE. (2009 [addendum 2014]). "The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment." from Loibl, S., N. Turner, J. Ro, M. Cristofanilli, H. Iwata and S. Im (2016). "Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy results from Paloma-3." J Clin Oncol 34(suppl): abstr 524. S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
10 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
11 Quellen: Gibson, L., D. Lawrence, C. Dawson and J. Bliss (2009). "Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women." Cochrane Database Syst Rev(4): Cd Hayes, D. F., I. C. Henderson and C. L. Shapiro (1995). "Treatment of metastatic breast cancer: present and future prospects." Semin Oncol 22(2 Suppl 5): 5-19; discussion Fossati, R., C. Confalonieri, V. Torri, E. Ghislandi, A. Penna, V. Pistotti, A. Tinazzi and A. Liberati (1998). "Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women." J Clin Oncol 16(10): Ellis, M., D. Hayes and M. Lippman (2000). "Treatment of metastatic breast cancer." Cancer 2000: Mouridsen, H., M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Janicke, A. Pluzanska, M. Dank, D. Becquart, P. P. Bapsy, E. Salminen, R. Snyder, M. Lassus, J. A. Verbeek, B. Staffler, H. A. Chaudri-Ross and M. Dugan (2001). "Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group." J Clin Oncol 19(10): S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
12 Quellen: Mouridsen, H., Y. Sun, M. Gershanovich, R. Perez-Carrion, D. Becquart, H. Chaudri-Ross, R. Lang, C. Brady and M. Dugan (2001). "First-line therapy with letrozole (femara ) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status compared with tamoxifen." Breast Cancer Research and Treatment 69(3): 291. NICE. (2009 [addendum 2014]). "The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment." from Rugo, H. S., R. B. Rumble, E. Macrae, D. L. Barton, H. K. Connolly, M. N. Dickler, L. Fallowfield, B. Fowble, J. N. Ingle, M. Jahanzeb, S. R. Johnston, L. A. Korde, J. L. Khatcheressian, R. S. Mehta, H. B. Muss and H. J. Burstein (2016). "Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline." J Clin Oncol 34(25): S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
13 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
14 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
15 S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 Dezember
Breast cancer has the highest incidence among those
Medical Treatment of Breast Cancer Young Seon Hong, M.D. Department of Internal Medicine Catholic University of Korea, St. Mary's Hospital E mail : y331@cmc.cuk.ac.kr Abstract Breast cancer has the highest
Okmeydani Training and Research Hospital, Medical Oncology Clinic, İstanbul, Turkey.
International Journal of Current Research and Review DOI: 10.7324/IJCRR.2018.1067 IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 ICV: 71.54 Research Article Fulvestrant Efficacy in Artificial
Metastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
When is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
FULL PAPER British Journal of Cancer (2014) 111, 2046 2050 doi: 10.1038/bjc.2014.502 Keywords: aromatase inhibitor; withdrawal response; breast cancer; hormone-receptor-positive tumours; metastatic; endocrine
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer in Korea
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 217;49(2):454-463 Original Article https://doi.org/1.4143/crt.216.259 Open Access Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women
Endocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
The efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
Pro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
Ovarian Ablation as Adjuvant Therapy for Breast Cancer
Ovarian Ablation as Adjuvant Therapy for Breast Cancer Nancy E. Davidson Ovarian ablation was the first form of systemic treatment for breast cancer. Its efficacy as a palliative treatment for young women
Sang Hee Kim*, Jihye Choi*, Chan Sub Park, Hyun-Ah Kim, Woo Chul Noh, Min-Ki Seong
ORIGINAL ARTICLE J Breast Dis 2018 December; 6(2): 46-51 JBD Journal of Breast Disease Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone- Releasing Hormone Agonist in Premenopausal Metastatic
Endocrine therapy in metastatic breast cancer: a closer look at the current clinical practice
Review Endocrine therapy in metastatic breast cancer: a closer look at the current clinical practice Hassan Ebrahim, MD Levine Cancer Institute-Cleveland, Shelby, North Caroli Endocrine therapy is a very
It is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
NCCP Chemotherapy Protocol
Letrozole Monotherapy INDICATIONS FOR USE: INDICATION Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. Extended adjuvant treatment of hormone-dependentinvasive
Update from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
Online-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
Weekly Paclitaxel in Pretreated Metastatic Breast Cancer: Retrospective Analysis of 52 Patients
Tohoku J. Exp. Med., 2004, Weekly 203, Paclitaxel 205-210 in Pretreated Metastatic Breast Cancer 205 Weekly Paclitaxel in Pretreated Metastatic Breast Cancer: Retrospective Analysis of 52 Patients ESMEN
A decade of letrozole: FACE
Breast Cancer Res Treat (2007) 105:67 74 DOI 10.1007/s10549-007-9702-9 REVIEW A decade of letrozole: FACE Joyce O Shaughnessy Received: 15 January 2007 / Accepted: 17 July 2007 Ó Springer Science+Business
Downloaded from:
Gibson, LJ; Dawson, C; Lawrence, DH; Bliss, JM (2007) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev, 1 (1). CD003370. ISSN 1469-493X DOI:
HORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
Review Article. Hormone Therapy in Breast Cancer. Rezumat
Review Article Chirurgia (2017) 112: 413-417 No. 4, July - August Copyright Celsius http://dx.doi.org/10.21614/chirurgia.112.4.413 Hormone Therapy in Breast Cancer Mãdãlina Drãgãnescu, Codruåa Carmocan
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
Letrozole in the extended adjuvant setting: MA.17
Breast Cancer Res Treat (2007) 105:45 53 DOI 10.1007/s10549-007-9698-1 REVIEW Letrozole in the extended adjuvant setting: MA.17 Paul E. Goss Received: 3 January 2007 / Accepted: 17 July 2007 Ó Springer
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
NCCP Chemotherapy Regimen. Palbociclib Therapy - 28 day
INDICATIONS FOR USE: Palbociclib Therapy - 28 day INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative
Adjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
Role of aromatase inhibitors in breast cancer
All rights reserved 0007 0920/05 $30.00 www.bjcancer.com R Carpenter 1 and WR Miller*,2 1 The Breast & Endocrine Unit, 2nd Floor West Wing, St Bartholomew s Hospital, London EC1A 7BE, UK; 2 Edinburgh Breast
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer
Original article Annals of Oncology 16: 1458 1462, 25 doi:1.193/annonc/mdi275 Published online 9 June 25 Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women
Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
Advances in chemotherapy for HER2-negative metastatic breast cancer
Review Article Page 1 of 5 Advances in chemotherapy for HER2-negative metastatic breast cancer Hirofumi Mukai, Mayuko Ito Department of Breast and Medical Oncology, National Cancer Center Hospital East,
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
Johns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study: Current Status of Treatment Selection in Japan
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/ Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study: Current Status of Treatment Selection
Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
British Journal of Cancer (2006) 94, 30 35 All rights reserved 0007 0920/06 $0 www.bjcancer.com Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
Kazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
Update on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
Efficacy and Tolerability of Weekly Paclitaxel in Combination with High-dose Toremifene Citrate in Patients with Metastatic Breast Cancer.
Efficacy and Tolerability of Weekly Paclitaxel in Combination with High-dose Toremifene Citrate in Patients with Metastatic Breast Cancer a,b* a,c a a a a,d a,e a,e a a b c d e ʼ 1 8 15 18 32 39 Treatment
Breast Cancer Advanced Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Advanced Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch How to Guidelines and Consensus Breast Cancer Advanced Disease Prognosis Clonal (and diagnostic) evolution: Biopsy
Outline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status 1
Research. [CANCER RESEARCH 63, 6523 6531, October 1, 2003] Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status 1 Matthew J. Ellis, 2 Andrew Coop,
Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical
1 2 1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast
SYNOPSIS PROTOCOL TALBOT
SYNOPSIS PROTOCOL TALBOT A) CLINICAL TRIAL IDENTIFICATION SPONSOR - PROTOCOL CODE NUMBER : VERSION: SYNOPSIS V4.0-30/06/2015 TRIAL TITLE : Open-label, randomized, multicenter, phase II study, comparing
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
Transcript and References
Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Co-director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine
The Role of Aromatase Inhibitor (AI) in The Treatment of Breast Cancer
R E V I E W A R T I C L E The Role of Inhibitor (AI) in The Treatment of Breast Cancer Cosphiadi Irawan, Abdulmuthalib INTRODUCTION Discussion on the topic with the same title above would never be separated
Introduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
Long Survival of Metastatic Breast Cancer in center of Tunisia, about 34 cases
Long Survival of Metastatic Breast Cancer in center of Tunisia, about 34 cases Hochlef M, Zaied S, Ben Fatma L, Rjiba R, Ezzairi F, Chabchoub I, Gharbi O, Ben Ahmed S Department of Oncological Medicine,
DOI: Tam Binh V Bui 1, Desirée MT Burgers 1, Mariette J Agterof 2 and Ewoudt MW van de Garde 1,3
823238BCB0010.1177/1178223418823238Breast Cancer: Basic and Clinical ResearchBui et al research-article2019 Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/
Current Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
Midwest Metastatic Breast Cancer Conference. Douglas Yee, M.D. Director Masonic Cancer Center University of Minnesota
Midwest Metastatic Breast Cancer Conference Douglas Yee, M.D. Director Masonic Cancer Center University of Minnesota Presented By: Title Sponsor: Historical Overview & Evolution of Metastatic Breast Cancer
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
Metastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
Aromatase inhibitors in breast cancer: Current and evolving roles
CURRENT DRUG THERAPY JOHN HILL, MD Department of Hematology and Medical Oncology, The Cleveland Clinic HALLE MOORE, MD Associate Professor, Department of Hematology and Clinical Oncology, The Cleveland
General introduction and scope of the thesis
1 General introduction and scope of the thesis 8 CHAPTER 1 General introduction and scope of the thesis Breast cancer epidemiology Breast cancer is the leading cancer diagnosis in women worldwide 1. Approximately
A Layperson's Guide to Endocrine (Hormone) Therapy
A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
Best of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
Anti-aromatase Agents in the Treatment and Prevention of Breast Cancer
Based on their activity in the metastatic setting, anti-aromatase agents are now being evaluated in the adjuvant setting and in pilot studies for chemoprevention. Michele Sassi. La Digue Island, c. 2001.
Bisphosphonates and other bone agents for breast cancer(review)
Cochrane Database of Systematic Reviews Bisphosphonates and other bone agents for breast cancer (Review) O Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A O Carrigan B, Wong MHF, Willson
Introduction. Shinzaburo Noguchi 1 Hee Jeong Kim. Nobuaki Sato 5 Hwei-Chung Wang. Ku Sang Kim 9 Yohji Itoh
Breast Cancer (2016) 23:771 779 DOI 10.1007/s12282-015-0637-4 ORIGINAL ARTICLE Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive
Management of metastatic breast cancer (MBC) Ali M. Al-Amri, MD. 1
Management of metastatic breast cancer (MBC) Review Article Ali M. Al-Amri, MD. 1 1 Department of Internal Medicine/Oncology, College of Medicine, University of Dammam, King Fahd Hospital of the University,
BREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2 negative breast cancer in postmenopausal women, first or second line
NIHR Innovation Observatory Evidence Briefing: August 2017 Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2 negative breast cancer in postmenopausal women, first or second line NIHRIO
10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
Approximately 70% of breast
Josh Lauring and Antonio C. Wolff Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer (J Clin Oncol 2016;34(25):2950 2952.)
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Perspective CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer Romualdo Barroso-Sousa, Sara M. Tolaney Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Correspondence
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
Key Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
Cohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
Page. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
Mechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
abstract n engl j med 373;3 nejm.org July 16,
The new england journal of medicine established in 1812 July 16, 2015 vol. 373 no. 3 Palbociclib in Hormone-Receptor Positive Advanced Breast Cancer Nicholas C. Turner, M.D., Ph.D., Jungsil Ro, M.D., Fabrice
Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
The Oncologist Breast Cancer Aromatase Inhibitors for Breast Cancer in Postmenopausal Women SUSANA M. CAMPOS Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Key Words.
Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer
![Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer](/thumbs/77/76517551.jpg "Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer")
Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer Dr Antonio Llombart-Cussac, MD, PhD Medical Oncology Division Hospital Arnau Vilanova, Valencia, Spain Disclaimer The contents herein
Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
Choosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
Cancer Biology 2016;6(2)
Efficacy of Adjuvant Zolodronic Acid in Post Menopausal Women with Early Breast Cancer Receiving Adjuvant Aromatas Inhibitor on Improving Bone Health Doaa Abdelrahman, Wael Elsawy, Yossra Taha Dorgham,
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
CLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Faslodex (fulvestrant) Policy Number: MP-044-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
Cover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29317 holds various files of this Leiden University dissertation. Author: Nes, Johanna Gerarda Hendrica van Title: Clinical aspects of endocrine therapy
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
Technology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy